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Abstract 
Background: Psychosocial factors have been linked with loss to follow-up (LTFU) and clinical outcomes among 
people living with HIV (PLH), however little is known about the effect of psychosocial support on LTFU among PLH in 
treatment and care. The purpose of this study was to explore the effect of NAMWEZA (“Yes, together we can”) friends’ 
psychosocial support intervention on clinical outcomes and LTFU among PLH. NAMWEZA is based on a novel pro-
gram using “appreciative inquiry”, positive psychology approaches to empower, promote positive attitudes and foster 
hope.
Methods: PLH participating in the NAMWEZA intervention in HIV care clinics in Dar es Salaam Tanzania were com-
pared with non-exposed PLH obtained from facilities that routinely collect clinical information and both followed lon-
gitudinally for 24 months. Baseline sociodemographic, clinical measures (CD4 cell count, hemoglobin (HGB), weight), 
and LTFU measures were collected. Chi square, Fisher’s exact tests, and t-tests were used to compare the frequencies 
for categorical variables and the means of continuous variables from the intervention and the comparison groups to 
identify variables that were significantly different across the two groups. Random effects models were performed to 
examine the bivariate associations between the intervention status and clinical outcomes.
Results: At the end of 24 months of follow-up mean CD4 count and HGB levels increased significantly in both 
intervention and comparison groups (p = 0.009 and p < 0.0001, respectively). Weight increased significantly only 
in the intervention group (p = 0.003). Cumulative LTFU was three times higher in the comparison compared to the 
intervention (p < 0.001) group. Having a low CD4 count, extremes of weight, low HGB, younger age, and male gender 
were significantly associated with LTFU among the unexposed group, while being on ART for duration of 12 months 
or more was protective against LTFU in those intervened.
Conclusion: Among PLH on ART, exposed or not exposed to NAMWEZA intervention, clinical care outcomes 
improved over time. LTFU was much higher in the comparison group with factors commonly known to predict LTFU 
only apparent in the comparison group. NAMWEZA could be a promising peer-facilitated model to reduce LTFU 
among PLH in care that can be integrated in ART services; however, more research is needed to evaluate its longer 
term effects.
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Background
Although there has been increased public and patients’ 
awareness of the benefits of antiretroviral therapy (ART) 
globally [1], in many countries attrition from ART care 
programs has been high, with loss to follow-up (LTFU) 
of patients listed as a leading cause [2–6]. However, ART 
can only be effective, resulting in virological suppression, 
if PLHs are highly adherent (commonly described as tak-
ing equal to or over 95% of ART medication) [7]. This 
level of drug adherence is very difficult to attain for PLH 
who are unable to sustain scheduled clinic follow-up vis-
its, as studies indicate that the majority of patients with 
LTFU stop their ART. Stopping ART has been reported 
to quickly increase the risk of developing high serum 
viral load and other adverse health consequences [2, 5, 8, 
9] including ART drug resistance, progression of HIV to 
AIDS, premature mortality, and re-infection, or infection 
of others with resistant strains [2–4, 10, 11].
In sub-Saharan Africa, LTFU is a factor reported to 
account for attrition from most ART programs than 
other causes [12–14] and varies for different groups of 
PLH. For instance LTFU ranges from 19 to 89% among 
women accessing Prevention of Mother-To-Child HIV 
transmission (PMTCT) services and 22% among HIV 
infected children [15]. In Tanzania, where this study 
was conducted, LTFU among PLH enrolled in ART care 
programs is estimated to be 49% and it varies with dura-
tion in ART care. About 18 and 36% of PLH in Tanza-
nia are reported to be LTFU at the end of their first 
and third year respectively after starting ART. A report 
published by the Ministry of Health and Social Welfare 
in 2012 indicated that attrition of patients due to death 
accounted for only a small percent of PLH that was lost 
from ART treatment (5–8%). Most attrition was due to 
other unknown causes resulting in the majority of the 
LTFU [14, 16].
Some of the factors reported to contribute to LTFU 
from ART care in Tanzania include individual factors 
such as advanced clinical and immunological disease 
stage, younger age, malnutrition, low education, depres-
sion, and poor psychological support [17–21]. The World 
Health Organization (WHO) reported other individual 
risk factors for LTFU from ART care commonly reported 
from resource-limited countries, including feeling bet-
ter, pill burden, treatment fatigue, work as well as home 
responsibilities, and migration—mobile populations 
(‘silent transfers’)—to other ART service providers [22]. 
Likewise system/infrastructural factors contributing 
to LTFU from ART care have been reported from East 
Africa. These include longer turnaround time of labora-
tory tests, drug stock outs, and clinics operating for less 
than 4  days a week [23] LTFU therefore results from 
complex individual and programmatic/system challenges 
facing PLH and ART programs that require greater effort 
to adapt effective interventions to maximize the benefit 
of ART programs for PLH and the role of ART as an HIV 
transmission prevention approach [3, 20, 24, 25].
Although a number of studies have reported LTFU 
and other ART treatment outcomes among PLH in Tan-
zania, most did not include assessments of additional 
interventions provided to PLH apart from routine ART 
care. Thus there is still limited information on effec-
tive interventions for PLH in care and receiving ART 
for reducing LTFU and improving other HIV treatment 
outcomes [8, 14]. In particular, those that influence psy-
chological factors that have been reported to predict HIV 
risk behaviors, poor adherence, low retention and poor 
treatment outcomes among PLH [26]. Providing psycho-
logical counselling, offering psychoeducation, facilitat-
ing psychosocial support and providing support to PLH 
to reduce psychosocial challenges including depression, 
anxiety, relationship/family turmoil and poor communi-
cation have been reported to increase adherence to ART 
[21, 27–30]; however, not much has been reported on 
how psychosocial interventions may impact LTFU and 
other HIV treatment outcomes in Tanzania.
The primary objective of our study was to examine 
associations between exposure to the NAMWEZA inter-
vention and HIV clinical outcomes as well as LTFU. In 
addition, factors associated with LTFU were assessed 
among PLH in Dar es Salaam, Tanzania.
Methods
Study design
We conducted a prospective cohort study involving 416 
HIV infected adult participants exposed to the NAM-
WEZA intervention and 408 HIV-positive unexposed 
‘comparison group’. The data for this analysis was col-
lected from January 2012 to December 2013 and were 
obtained from NAMWEZA intervention electronic 
records and National HIV care electronic database 
known as CTC2 available at each of participating sites.
Eligibility criteria
Both NAMWEZA exposed and unexposed partici-
pants were eligible if HIV infected, 18  years of age and 
above, living in the catchment area of the HIV care and 
treatment center (CTC), registered for HIV care and 
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treatment at the study CTCs, initiated on ART and had 
used ART for at least 3  months (enrolment criteria for 
both NAMWEZA exposed and controls), and resident 
in the Kinondoni District. The ART regimen and other 
standard HIV related health care services were provided 
similarly between the two groups. Exclusion from the 
study occurred if poor health prohibited participant’s 
recruitment, if they had not started ART and for the 
NAMWEZA exposed, if unable to provide informed con-
sent for participation, and not planning to remain resi-
dent for at least 2 years in the Kinondoni District.
Methods of follow up
Both the intervention and control participants were 
seen monthly at the clinic for routine ART care during 
the time period of follow-up (January 2012 to December 
2013). HIV care included adherence counseling, seeing a 
physician for any health concerns, providing laboratory 
tests as scheduled and any other tests that a physician 
might feel the patient needs at that visit. Each clinic has 
trained and experienced community based health work-
ers (CHWs) who tracked missing PLH. At the time of the 
study, data were collected prospectively from the clinical 
databases. The CHW worked with the clinic data clerks 
under the supervision of the clinic nurse in-charge to 
obtain daily lists of PLH who miss their scheduled clinic 
visits. After obtaining the list, they followed up the miss-
ing patients through phone calls (1 week after missing a 
scheduled clinic visit) and a home visit 2  weeks after a 
missed clinic appointment if phone calls were unsuccess-
ful and or the patient didn’t come to the clinic. The CHW 
provided reports that were entered into the CTC2 data-
base daily to update patients’ vital status (i.e. not ascer-
tained, ascertained alive or died). The CHW continued 
to track those not found for three or more months after 
which if vital status could not be ascertained they are 
declared LTFU.
Exposure variable
NAMWEZA, pronounced as two linked words NAM-
WEZA (Yes I can!), is an intervention that includes 10 
once weekly structured sessions aimed at empowering 
PLH to become HIV prevention change agents in their 
communities. Psychosocial issues related to relationships 
and living with HIV as well as change agent’s commu-
nication skills building occurred using an Appreciative 
Inquiry (AI) approach. The AI model engages stake-
holders in self-determined change and was first used 
to change organizational/system behavior. It involves 
searching for the best in people, and the world around 
and systematic discovery of what gives a system ‘life’ 
when it is most effective and capable in economic, eco-
logical, and human terms. Participants receive training 
sessions that targets developing the art and practice of 
asking questions that strengthen an individual or a sys-
tem’s capacity to heighten positive potential [31, 32]. The 
AI model components used in the process of delivery 
of NAMWEZA group sessions, included strategies that 
built participants skills to ask reflective and apprecia-
tive questions about what is working well in themselves, 
people’s lives specifically their social network members 
and through the answers, identify and affirm abilities 
in self and others; and using dreams about the future 
and backlighting to focus action plans for change in the 
here and now. Participants used appreciative inquiry 
to explore their abilities potentials, dream for and draw 
feasible action plans for the future including abilities to 
access and manage microfinancing keep healthy relation-
ships, Burgan for safer sexual practices, and handling 
HIV infection and disclosure. Also NAMWEZA fostered 
resilience and social support through building partici-
pant’s communication skills in the use of “I” rather than 
“You” statements to improve clarity and reduce conflict 
when communicating with others. All sessions include 
repeated exercises and role plays practiced during the 
sessions, with each session building on the previous one. 
Participants were encouraged to practice the skills of 
each session at home and give feedback before the begin-
ning of the next session. This approach aims to increase 
self-confidence and self-esteem as a way of exploring, 
highlighting, and developing skills as resources within 
each session theme [33]. The thematic content of NAM-
WEZA included themes that ranged from exploring love, 
relationships, sex, and feelings in session 1 to action plan-
ning in a closing session 10 (see Table 1).
Sessions were highly participatory and active 
learning occurred with the opportunity to practice 
learned skills and provide feedback in subsequent 
sessions. Training occurred in age and gender spe-
cific groups (women  <35  years of age; men  ≤35  years; 
women ≥35 years; and men ≥35) to foster group cohe-
sion through shared experiences. Groups were facilitated 
by trained peer PLH. NAMWEZA exposed participants 
attended 1–10 sessions, with an average of 7.7 sessions; 
while the comparison group did not attend any ses-
sions. All the sessions were available to all participants, 
who were informed of the dates and times and expected 
to attend all the 10 sessions. In addition, both the NAM-
WEZA exposed PLH and the comparison group received 
routine ART care including monthly prescriptions for 
medications, as well as other aspects of clinical care and 
ART adherence counseling sessions.
Outcome variables
Loss to follow-up (LTFU), immunological (CD4), and 
other clinical outcomes including weight, hemoglobin 
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level, and number of scheduled clinic visits attended were 
examined. For this study a patient was LTFU if he/she 
did not attend three scheduled clinic visits in three con-
secutive months with no reported/documented death or 
transfer out [34].
Data collection
Outcome data were obtained from the CTC electronic 
database which contains routinely collected clinical data 
for PLH accessing care at each of the participating sites. 
Data for sociodemographic measures, duration on ART, 
and all outcome variables including CD4, weight, and 
hemoglobin levels; as well LTFU measures were extracted 
from the database at 8, 16, and 24 months of follow-up.
Data analysis
Descriptive statistics for sociodemographic factors and 
clinical variables were estimated at baseline, includ-
ing frequencies for categorical data as well as means 
and standard deviations for continuous variables. Chi 
square, Fisher’s exact tests, and t-tests were used to 
compare the frequencies for categorical variables and 
the means of continuous variables from the interven-
tion and the comparison groups to identify variables that 
were significantly different from the two groups. Random 
effects models were performed to examine the bivariate 
associations between the intervention status and clini-
cal outcomes, including CD4 cell count, weight change, 
HGB levels, and LTFU. In the multivariate models vari-
ables that had a p value of 0.2 or less at baseline for the 
intervention and comparison groups were controlled for. 
In addition, a missing variable indicator was included 
to address missing data and logistic regression models 
were used to predict factors associated with LTFU for 
intervention and comparison groups. A Kaplan–Meier 
survival curve was used to estimate retention among the 
intervention and comparison groups. We also examined 
factors associated with LTFU using Cox proportional 
hazards regression models. SAS statistical software (ver-
sion 9.3) was used for the analysis [35].
Results
All 450 HIV-positive participants of NAMWEZA inter-
vention were eligible to participate. Thirty-four (7.5%) of 
the exposed participants had absent or incomplete clini-
cal information and were dropped from the analysis. The 
final number of participants in the intervention group 
included in this study was 416 (92%). A total of 408 PLH 
were identified from the CTC2 database based on the 
same eligibility criteria.
At baseline, only gender and age variables were sta-
tistically significant different from the intervention and 
Table 1 Summary of the contents of each NAMWEZA Training Session
Session 1 An introductory session: which include welcoming the participants, setting ground rules participants sharing life stories and group lived 
values, the story of the 5th province, whom do you hear calling your name and an introduction of appreciative inquiry in communica-
tion, how to spot abilities of others, dreaming positively for future, and how to be wise
Session 2 Titled Love relationship and emotions: include more training to use appreciative inquiry in communication, exploring values of love and 
how to view emotions from self and others (anger, sadness), as an invitation and a communication instead of an attack, and how to 
communicate back
Session 3 Titled Valuing others and self: include sharing experiences that influence life, how we value ourselves, how we value our own words and 
imagined negotiation
Session 4 Titled Happiness, safer sexual relationships, healthy living; include drawing a map of safer and happy living, appreciative inquiry, follow-
ing direction education and discussions on HIV transmission and prevention myths and facts about HIV, following directions, positive 
networking and condom use
Session 5 Titled Developing assertiveness skills; revisions and role plays on appreciative inquiry, ability spotting, exploring hopes and fear, taking 
control during communications by using proper posture, eye contact and voice tones, I see, I feel, I want, putting things into practice 
drawing bodies as roadmap for sexually learning
Session 6 Titled Deepening and expanding assertiveness skills: More revision and role plays on appreciative inquiry, ability spotting, wider assertive 
skills building including manipulative how to manage an ambiguous situation, pushing the line during communication and entrepre-
neurial future
Session 7 Titled Disclosure 1; of an HIV positive status; confidentiality, appreciative inquiry, good care giver, human rights, telling and listening, how 
to become a good listener
Session 8 Titled Disclosure 2; challenges and positive possibilities, taking care of self, how to tell family and close relatives, sexual partners, support-
ing each other and spiders web
Session 9 Titled Visualizing; targets on focusing the participants to explore, reflect skills and resources in them and others, and create a microeco-
nomic plan. This involve visualizing and drawing hoped for community/work, Appreciative inquiry exploring income generating skills 
including how to access and manage microfinances
Session 10 Titled The future; This is the final session that focuses on what has been learned during the all the other sessions by revisiting the tree of 
life and future possibilities for advocacy. Participants revisit and add on the previously tree of live adding their abilities and building on 
dreams and creating action plans for the future, mental gifts, tree of abilities and how to move in the community
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comparison groups (p = 0.03 and <0.0001, respectively). 
The other demographic characteristics were not signifi-
cantly different (Table  2). Seventy-two percent and 77% 
of the participants from intervention and comparison 
groups respectively were females. The mean age was 46 
and 37  year for intervention and comparison groups, 
respectively. About half (49%) of intervention and slightly 
above 50% (52%) of the comparison group, reported to 
be living with a sexual partner in a marital or cohabit-
ing relationship. Majority of the participants in both the 
intervention and comparison groups reported that they 
were self-employed; 38 and 41% respectively, followed by 
those who were employed (35 and 36%) respectively, a 
few were house wives/husbands (9 and 11%) respectively 
and unemployed were 15% in the intervention and 16% in 
the comparison group (Tables 2, 3).
For the clinical outcome variables baseline CD4 cell 
count in the intervention and control groups was 308 
and 270  cells/mm3, respectively; and mean hemoglobin 
(HGB) levels were 9  g/dl for the intervention and 10  g/
dl for the comparison group. The mean body weight of 
the participants was 61 and 60 kg in the intervention and 
control groups respectively. Similar to most demographic 
variables, the clinical parameters were not significantly 
different in the two groups (Table 3).
The mean duration on ART medication was 20 months 
in the intervention and 18  months in the compari-
son group (p  =  0.23). The median follow up time was 
20.2 months in the intervention and 23.3 months in the 
intervention group (Table 6). The average number of rou-
tine clinic visit made was significantly higher at 22.8 visits 
in the intervention group, compared to 16.9 visits in the 
comparison group (p = 0.003) (Table 6).
Multivariate analyses showed that CD4 counts 
increased significantly in both the intervention and com-
parison groups over time (p = 0.0024 and 0.047, respec-
tively). However, women in both groups had significantly 
faster rates of CD4 count increase of about 41 cells/mm3 
per month compared to men (p = 0.005) (Table 4). Over 
time, participants in the intervention group had signifi-
cantly higher weight gain of (0.270  kg per month com-
pared to 0.140 kg in the comparison group (p = 0.003). 
At the end of follow-up, the proportion of PLH who 
Table 2 Baseline sociodemographic characteristics for  PLH 
receiving HIV treatment in Dar es Salaam, Tanzania
1 p value obtained from Fisher’s exact test
2 p value was obtained from Chi Square test
a A total of eight participants from the comparison group and eight from the 
intervention with missing data were omitted
Characteristic Comparison 
group, N = 408 
n (%)/mean (SD)
Intervention, 
N = 416 
n (%)/mean (SD)
p value
District of residence
 Kinondoni 387 (95.3) 412 (99.8)
 Ilala 10 (2.5) 1 (0.24) 0.08971
 Temeke 9 (2.2) 0 (0.0)
Sex
 Male 92 (23.0) 116 (28.0) 0.03012
 Female 316 (77.0) 300 (72.0)
Mean age 37 (9.1) 46 (9.7) <0.00012
Age groups in years <0.00012
 <30 30 (11.3) 30 (7.2)
 ≥30 236 (88.7) 386 (92.8)
Marital statusa
 Lives with partner 
(married or 
cohabiting)
208 (52.0) 205 (49.2) 0.30002
 Single (never 
married or 
widowed)
192 (48.0) 203 (48.7)
Employment status
 Employed 142 (34.8) 148 (35.6)
 Self-employed 166 (40.7) 156 (37.5) 0.65102
 House wife/house 
husband
35 (8.6) 45 (10.8)
 Unemployed 65 (15.9) 67 (16.1)
Table 3 Baseline clinical characteristics for  PLH receiving 
ART care in Dar es Salaam, Tanzania
N-intervention group = 412 and 367 control group: A total of 21 participants 
in the comparison group and 4 in the intervention had missing data and were 
omitted 
1 p-value was obtained from Chi Square test
Characteristics Comparison Intervention p value1
Mean CD4 (SD) 270 (173.4) 308 (184.1) 0.76
Immune suppression
 Severe immunosuppression 
(CD4 < 200)
116 (28.5) 96 (23.1) 0.09
 Moderate immune suppres-
sion (CD4 = 200 to <350)
119 (29.2) 138 (33.2)
 Not immune suppressed 
(CD4 ≥ 350)
173 (42.4) 182 (43.8)
Mean hemoglobin (SD) 10 (2.1) 9 (1.9) 0.09
Low hemoglobin(anemia) 
mean (SD)
11 (2.6) 5 (1.2)
 Severe anemia (<8.5) 60 (14.7) 52 (12.5) 0.03
 Moderate anemia (8.6 to <10) 179 (43.9) 278 (88.8)
 Mild anemia (10 to <12) 122 (29.9) 81 (19.5)
No anemia (>12) 44 (9.0) 91 (22.0)
Mean weight (kg) (SD) 60 (11.9) 61 (12.7) 0.33
Weight groups (kg) 0.21
 <45 72 (18.6) 21 (5.1)
 45–60 88 (21.6) 50 (12.0)
 >60 227 (55.6 341 (82.0)
Mean duration on ART at 
baseline, mean (SD)
18 (17.0) 20 (16.0) 0.23
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were LTFU was significantly lower in intervention (4.8%) 
compared to (14.7%) in the control group (p  =  0.002) 
(Table  6). More PLH were retained in the interven-
tion compared to the control group as depicted by the 
Kaplan–Meier curve in Fig. 1. In the intervention group, 
the proportion of LTFU was significantly higher (57%) 
among the participants who attended 1–6 NAMWEZA 
training sessions than those who attended 7–10 sessions 
(43%), p = 0.033 (Table 6).
For LTFU, five out of the six factors that were associ-
ated with LTFU, were only significant in the control par-
ticipants, but not the intervention group participants. 
These included: low CD4; PLH with severe immune 
suppression (CD4  <  200  cells/mm3 had higher risk of 
LTFU (p  <  0.0001); extremes in weight, where those 
with extreme low or high weights (<45 and >60 kg) were 
at higher risk of LTFU (p = 0.02); low hemoglobin; par-
ticipants with lower hemoglobin levels (<10  mg/dl) 
showed higher risk of LTFU (p  =  0.01). Male gender 
was associated with higher risk of LTFU (p = 0.04) and 
younger age (<40  years) was associated with higher 
LTFU risks (p  =  0.03). In the intervention group, PLH 
with longer duration of ART use, experienced less LTFU 
(p  <  0.0001), while in the comparison group, persons 
with longer duration on ART were at higher risk of LTFU 
(p < 0.0001) (see Tables 5, 6).
Discussion
This study examined associations between exposure to 
a peer facilitated psychosocial intervention and clini-
cal outcomes among PLH receiving ART. Participants 
exposed to the NAMWEZA intervention saw significant 
improvement in clinical outcomes that were not seen 
among those who did not receive the NAMWEZA inter-
vention. Weight gain, CD4 counts, and hemoglobin all 
significantly increased among NAMWEZA participants, 
whereas smaller non-significant gains were seen in the 
comparison group. The NAMWEZA intervention had 
Table 4 Univariate and multivariate analyses of intervention vs. comparison group
1 p value obtained from random effects model
Covariate of interest Univariate Multivariate
Effect estimate p value Effect estimate p value1
CD4 count (cells/mm3)
 Intervention vs. comparison
 CD4 change over time
24.6 (−37.02, 86.23) 0.4337 26.9 (−36.31, 90.19) 0.4036
  Intervention 2.9 (1.19, 4.64) 0.0009 2.7 (0.96, 4.45) 0.0024
  Comparison group 2.8 (0.84, 4.75) 0.0051 2.8 (0.87, 4.79) 0.047
 Age −0.58 (−1.72, 0.56) 0.3196
 Gender 40.56 (12.41, 68.72) 0.0048
Weight (kg)
Intervention vs. comparison
Weight change over time
0.9 (−6.97, 8.71) 0.8270 −2.64 (−9.91, 4.620) 0.4757
  Intervention 0.14 (−0.073, 0.35) 0.2000 0.27 (0.09, 0.44) 0.0025
  Comparison group 0.15 (−0.03, 0.31) 0.0968 0.14 (−0.34, 0.31) 0.1234
 Age 0.08 (−0.01, 0.17) 0.0681
 Gender −0.79 (−3.04, 1.46) 0.4892
Hemoglobin (HGB) (in g/dl)
Intervention vs. comparison HGB change over time 0.12 (−1.60, 2.05) 0.8109 0.23 (−1.61, 2.06) 0.7268
  Intervention 0.03 (−0.02, 0.09) 0.2726 0.031 (−0.02, 0.09) 0.0429
  Comparison group 0.02 (−0.01, 0.05) 0.1154 0.020 (−0.01, 0.05) 0.0437
 Age (in years) 0.01 (−0.01, 0.03) 0.2026
 Gender −0.61 (−1.05, −0.18) 0.006
Lost to follow-up
 Intervention vs. comparison 0.62 (0.51, 0.76) <0.0001 0.64 (0.52, 0.78) <0.001
LTFU change over time
  Intervention 0.92 (0.91, 0.93) <0.0001 1.01 (1.01, 1.03) 0.0033
  Comparison group 0.93 (0.51, 0.76) <0.0001 0.92 (0.92, 0.93) <0.001
 Age 0.99 (1.00, 1.001) 0.1737
 Gender 0.95 (0.89, 1.02) 0.3169
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lower LTFU rates and participants were more likely to 
remain in treatment. The NAMWEZA protective effects 
against LTFU had a dose–response effect with lower 
rates observed among those who attended more of the 
NAMWEZA sessions.
In studies that have reported ART clinical outcomes 
among PLH, low CD4, younger age, male gender, low 
HGB, and weight were commonly reported to be asso-
ciated with LTFU [8, 14, 24, 36]. In this study these risk 
factors for LTFU were all independently significantly 
associated with LTFU among PLH in the comparison 
group but were not found for intervention group partici-
pants. These findings are similar to other studies report-
ing ART treatment outcomes and rates of LTFU [8, 14, 
36]. In addition, the cumulative rates of LTFU were three 
times higher in the comparison group as compared to 
the intervention group. This is also reflected in the aver-
age number of clinic visits which was significantly lower 
among the comparison group.
This variation could be related to the effect of exposure 
to the psychosocial intervention (NAMWEZA) in addi-
tion to routine ART care, and suggests that NAMWEZA 
may have had an effect on reducing LTFU in HIV care. 
Such interventions could be considered for integration 
within the ART care and treatment clinics to reduce 
LTFU.
The observed increase in CD4 counts and hemoglobin 
levels in both groups was expected since participants in 
both groups were receiving ART medications and were 
likely to show clinical improvements related to the dura-
tion of treatment [15, 37, 38]. However, the intervention 
group participants showed a higher increase in both CD4 
counts and hemoglobin levels compared to the control 
group. Close follow up of PLH during the NAMWEZA 
intervention could have prompted more clinic visits 
and greater adherence to ART by exposed participants 
compared to unexposed group participants. Further-
more, the intervention addressed psychosocial concerns 
which have been reported to hinder adherence to ART 
and retention in care [21]. This is similar to what was 
observed in Zimbabwe and Zambia where a psychosocial 
intervention known as “mothers2mothers” (m2m) was 
found to improve retention and adherence to the Option 
B+ antiretroviral regimens among HIV infected women 
[39, 40]. Although these studies were based on pregnant 
and breastfeeding women, the participants were tak-
ing a full regimen of ART similar to participants in this 
study. Better management of psychosocial concerns in 
the intervention group could also explain the significantly 
higher weight gain over time for NAMWEZA when com-
paring participants to those in the unexposed group.
Fig. 1 Kaplan Meier curve; showing LTFU in the intervention group (blue) and Comparison group (red)
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To our knowledge this is the first intervention study 
where PLH receiving ART medication were provided a 
psychosocial intervention that showed improvements in 
selected ART treatment outcomes. The study took place 
in an area which has a high HIV prevalence, especially 
among women, and a significant number of PLH receiv-
ing ART medications for varying durations.
There are a number of limitations for this study. 
The routinely collected clinical data used to select 
participants for this study had many gaps in informa-
tion since the purpose of data was for clinical care and 
not research. We excluded from the analysis of this 
study (both intervention and control arms), participants 
who had more than 50% missing information in the 
12 months before the study, perhaps limiting the repre-
sentativeness of the study results. Although the study is 
observational, major confounders have been controlled 
for in the study, and selection of participants according 
Table 5 Factors associated with LTFU among the intervention and comparison group participants
1 p value was obtained from Chi square test
Factor Intervention Comparison group
Univariate HR  
(95% CI)
p value Multivariate HR 
(95% CI)
p value Univariate HR  
(95% CI)
p value Multivariate HR 
(95% CI)
p value1
CD4 0.01 0.12 <0.001 <0.0001
 <200 0.75 (0.54, 0.03) 1.55 (1.11, 2.15) 3.20 (2.52, 4.53) 2.13 (1.63, 2.75)
 200 to <350 0.31 (0.21, 0.45) 0.86 (0.58, 1.27) 2.52 (1.98, 3.21) 1.83 (1.41, 2.36)
 350+ Reference Reference Reference Reference
Weight WT 0.83 0.65 0.001 0.0200
 <45 0.98 (0.99, 1.02) 0.29 (0.02, 0.32) 0.96 (0.68, 1.36) 1.48 (0.95, 2.31)
 45–60 Reference Reference Reference Reference
 60+ 0.94 (0.97, 2.03) 0.34 (0.03, 2.01) 1.60 (1.31, 1.96) 2.01 (1.63, 2.49)
HBG 0.74 0.09 <0.001 <0.000
 <8.5 1.11 (0.60, 2.07) 1.93 (0.91, 3.67) 0.40 (0.38, 0.43) 3.24 (2.97, 3.55) 1
 8.5 to <10 0.68 (0.47, 0.99) 0.10 (0.06,0.16) 0.44 (0.42, 0.46) 0.48 (0.46, 0.51)
 10 to <12 1.91 (1.32, 2.77) 1.17 (1.11, 0.26) 0.57 (0.55, 0.60) 1.00 (0.95, 1.05)
 12+ Reference Reference Reference Reference
ART duration <0.0001 <0.0001 <0.0001 <0.001
 <12 Reference Reference Reference Reference
 12+ 0.39 (0.27–0.57) 0.42 (0.28–0.63) 2.34 (1.98–0.21) 2.51 (1.84–0.43)
Gender <0.000 0.0400
 Male 0.02 (0.01–10.47) 0.85 1.49 (1.22–0.82) 1 1.28 (1.01–0.63)
 Female Reference Reference
Age 0.89 0.002 0.0300
 <30 3.31 (0.01–0.67) 0.87 (0.64–0.99) 0.73 (0.54–0.99)
 30 to <40 3.23 (0.01–0.23) 0.92 (0.79–0.15) 0.89 (0.69–0.14)
 40 to <50 Reference Reference Reference
 50+ 5.21 (0.02–0.23) 0.24 (0.06–0.38) 0.14 (0.06–0.35)
Table 6 Cumulative attendance of  scheduled clinic visits, LTFU, LTFU by  sessions at  and follow up  time the end of  the 
24 months among the intervention and comparison groups
1 p value obtained by Chi square test
Control Intervention p value1
Average number of scheduled visits in months, n (SD) 16.9 (6.27) 22.8 (2.01) 0.0030
Cumulative lost to follow up by end of 24 months, n (%) 60 (14.7) 20 (4.8) 0.0016
LTFU among those who attended 1–6 sessions, n (%) 12 (60) 0.0330
LTFU among PLH attending 7–10 sessions, n (%) 8 (40)
Median follow up time (months) 23.3 20.2 0.6800
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to the same eligibility criteria may have reduced poten-
tial bias.
Conclusions
The findings suggest that providing additional psycho-
social support to PLH receiving ART can reduce LTFU. 
Such support needs to be formalized and integrated with 
HIV treatment and care. In addition, working with peer 
supporters in this context was feasible and is likely gener-
alizable to other resource-limited settings with a signifi-
cant burden of HIV. Facilitating such interventions could 
in the long run reduce expenditures due to adverse health 
outcomes resulting from LTFU in HIV care.
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